These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 21034447)

  • 1. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
    Tashkin DP; Fabbri LM
    Respir Res; 2010 Oct; 11(1):149. PubMed ID: 21034447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
    Malerba M; Radaeli A; Morjaria JB
    Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
    Fuso L; Mores N; Valente S; Malerba M; Montuschi P
    Curr Med Chem; 2013; 20(12):1477-95. PubMed ID: 23409722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM; Mavergames C; Walters JA
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010177. PubMed ID: 24127118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
    Ribeiro M; Chapman KR
    Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB; Kanner RE
    Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Wu J; Ye Y; Li C; Zhou W; Chang R
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.
    Beier J; Beeh KM
    Int J Chron Obstruct Pulmon Dis; 2011; 6():237-43. PubMed ID: 21814459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indacaterol: a comprehensive review.
    Rossi A; Polese G
    Int J Chron Obstruct Pulmon Dis; 2013; 8():353-63. PubMed ID: 23922496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.
    Decramer ML; Hanania NA; Lötvall JO; Yawn BP
    Int J Chron Obstruct Pulmon Dis; 2013; 8():53-64. PubMed ID: 23378756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.